Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Gliflozins in Cardiac and Renal Disease Gliflozins—sodium–glucose cotransporter 2
inhibitors—lower blood glucose and glycated hemoglobin in patients with type 2 diabetes …

Background There is a paucity of evidence for dose and pace of up-titration of guideline-
directed medical therapies after admission to hospital for acute heart failure. Methods In this …

Background SGLT2 inhibitors are strongly recommended in guidelines to treat patients with
heart failure with reduced ejection fraction, but their clinical benefits at higher ejection …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

Aims No therapy has shown to reduce the risk of hospitalization for heart failure across the
entire range of ejection fractions seen in clinical practice. We assessed the influence of …

The ongoing obesity epidemic represents a global public health crisis that contributes to
poor health outcomes, reduced quality of life, and> 2.8 million deaths each year. Obesity is …

Nearly half of all patients with heart failure (HF) have a normal left ventricular (LV) ejection
fraction (EF) and the condition is termed heart failure with preserved ejection fraction …

Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …